Dare Bioscience Nasdaq/NYSE Compliance Notice
Daré Bioscience received a deficiency notice from Nasdaq on September 28, 2026, because its common stock closing bid price fell below the $1.00 minimum requirement for 30 consecutive business days. The company has until March 29, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The notice has no immediate effect on the listing, and the company may be eligible for an additional 180-day compliance period if necessary.
- Counterparty
- Nasdaq
- Term
- 180 days